Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pds Biotechnology Corp (NQ: PDSB )

3.730 +0.110 (+3.04%)
Streaming Delayed Price Updated: 10:49 AM EDT, Oct 6, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 63,970
Open 3.600
Bid (Size) 3.720 (18)
Ask (Size) 3.740 (5)
Prev. Close 3.620
Today's Range 3.600 - 3.770
52wk Range 2.890 - 14.80
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Global Cervical Cancer Treatment Market Size Expected to Reach $11 Billion By 2027
Palm Beach, FL – October 6, 2022 – FinancialNewsMedia.com News Commentary – The global Cervical Cancer Treatment market has been expanding for several years and is projected to continue at a growing... 
Via FinancialNewsMedia
PDS Biotechnology: Q2 Earnings Insights
  PDS Biotechnology (NASDAQ:PDSB) reported its Q2 earnings results on Monday, August 8, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga

Performance

YTD
-55.75%
-55.75%
1 Month
-7.44%
-7.44%
3 Month
-6.28%
-6.28%
6 Month
-38.75%
-38.75%
1 Year
-74.01%
-74.01%

More News

Read More
Earnings Outlook For PDS Biotechnology
Via Benzinga
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
PDS Biotechnology Gains On FDA Fast Track Designation For Lead Candidate
Via Benzinga
Recap: PDS Biotechnology Q1 Earnings
Via Benzinga
Earnings Scheduled For August 8, 2022
Via Benzinga
Earnings Scheduled For May 11, 2022
Via Benzinga
PDS Biotechnology: Q4 Earnings Insights
Via Benzinga
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
Via Benzinga
The Daily Biotech Pulse: Veru Seeks Emergency Use Nod For COVID-19 Therapy, Vincerx Cuts Workforce, Moderna Starts Dosing In Flu Vaccine Study
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
77 Biggest Movers From Yesterday
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine
Via Benzinga
What Were Your Best And Worst Stock Buys? What Does The Zinger Nation Think?
Via Benzinga
The Daily Biotech Pulse: Amylyx Announces Negative Adcom Vote, Clovis Jumps On Ovarian Cancer Data, Masimo Warns Of Q1 Shortfall
Via Benzinga
Earnings Scheduled For March 31, 2022
Via Benzinga
Earnings Outlook For PDS Biotechnology
Via Benzinga
The Daily Biotech Pulse: Roche's Lung Cancer Combo Therapy Flunks Late-Stage Study, Adagio Spikes On Positive COVID Antibody Data, Amylyx Awaits Adcom Verdict
Via Benzinga
The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
Via Benzinga
PDS Biotechnology Earnings Conference Call Is Coming Up, Here's What You Need To Know
Via Benzinga
Earnings Scheduled For March 23, 2022
Via Benzinga
Earnings Preview For PDS Biotechnology
Via Benzinga
The Week Ahead In Biotech (March 20-26): Focus On Zogenix FDA Decision, Dermatology Conference Presentations & Earnings
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.